{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:20:50Z","timestamp":1789402850436,"version":"build-2803163510"},"reference-count":42,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To analyze available literature on the use of direct oral anticoagulants (DOACs) in the treatment of confirmed or suspected heparin-induced thrombocytopenia (HIT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>PubMed and Embase databases were searched through December 16, 2024, to identify studies assessing DOAC use in the treatment of acute confirmed or suspected HIT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Included studies analyzed use of apixaban, dabigatran, edoxaban, or rivaroxaban in patients with confirmed or suspected HIT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Ten studies including 275 patients met the inclusion criteria. Eight were retrospective cohort studies and 2 were prospective. No randomized control trials were identified. A 4Ts score was reported for 259 patients; an antibody immunoassay was reported for 149 patients; and a serotonin release assay was reported for 109 patients. Eight, 6, and 2 studies reported use of rivaroxaban, apixaban, and dabigatran, respectively. Thrombosis rates ranged from 0% to 8.3%, 0% to 13.7%, and 0% to 2.5% for rivaroxaban, apixaban, and dabigatran respectively. Major bleeding was reported in 1 patient receiving rivaroxaban.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>The 2018 American Society of Hematology HIT guidelines conditionally recommend DOAC use due to very low certainty of effects. Direct oral anticoagulants (DOACs) are an attractive treatment option for acute HIT due to ease of administration and reduced need for monitoring. Analysis of the recently published relevant data can support and guide appropriate use of DOACs in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This systematic review strengthens previously published evidence that DOACs are likely a safe and effective treatment for confirmed or suspected HIT. Study design, small study size, and varying diagnostic criteria reduce data certainty.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251322549","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T08:05:41Z","timestamp":1748073941000},"page":"1015-1030","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Systematic Literature Review of DOACs as Treatment for Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT)"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1905-5740","authenticated-orcid":false,"given":"Shoshana","family":"Steinmetz","sequence":"first","affiliation":[{"name":"College of Pharmacy, Touro University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7358-8018","authenticated-orcid":false,"given":"Anastasiya","family":"Shor","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Touro University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7167-5359","authenticated-orcid":false,"given":"Michelle","family":"Jakubovics","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Touro University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.668"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024489"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2014.917181"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2020.04.014"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1411910"},{"key":"e_1_3_4_7_2","unstructured":"Nicolas D Nicolas S Hodgens A et al. Heparin-Induced Thrombocytopenia. StatPearls Publishing; 2024. Updated May 16 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482330\/"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2303"},{"key":"e_1_3_4_9_2","unstructured":"Child Health and Human Development. Drugs and Lactation Database (LactMed\u00ae) [Internet]. Lepirudin. National Institute of Child Health and Human Development; 2006. Updated 2023 Jul 15. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500999\/"},{"key":"e_1_3_4_10_2","unstructured":"National Institute of Child Health and Human Development. Drugs and Lactation Database (LactMed\u00ae) [Internet]. Desirudin. National Institute of Child Health and Human Development; 2006. Updated July 15 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500773\/"},{"key":"e_1_3_4_11_2","unstructured":"Wolters Kluwer Health Inc. Danaparoid UpToDate Lexidrug. Wolters Kluwer Health Inc; 2024. Updated March 14 2024. Accessed March 19 2024. http:\/\/online.lexi.com\/"},{"key":"e_1_3_4_12_2","volume-title":"Argatroban Package Insert","author":"Intas Pharmaceuticals Limited.","year":"2022","unstructured":"Intas Pharmaceuticals Limited. Argatroban Package Insert. Intas Pharmaceuticals Limited; 2022."},{"key":"e_1_3_4_13_2","volume-title":"Bivalirduin Package Insert","author":"Dr. Reddy\u2019s Laboratories Inc","year":"2019","unstructured":"Dr. Reddy\u2019s Laboratories Inc. Bivalirduin Package Insert. Dr. Reddy\u2019s Laboratories Inc; 2019."},{"key":"e_1_3_4_14_2","unstructured":"Wolters Kluwer Health Inc. Bivalirudin Uptodate Lexidrug. Wolters Kluwer Health Inc; 2024. Updated March 19 2024. Accessed March 19 2024. http:\/\/online.lexi.com\/"},{"key":"e_1_3_4_15_2","volume-title":"Fondaparinux Package Insert","author":"Dr. Reddy\u2019s Laboratories Inc","year":"2022","unstructured":"Dr. Reddy\u2019s Laboratories Inc. Fondaparinux Package Insert. Dr. Reddy\u2019s Laboratories Inc.; 2022."},{"key":"e_1_3_4_16_2","volume-title":"Eliquis (Apixaban) Package Insert","author":"Bristol Myers Squibb.","year":"2021","unstructured":"Bristol Myers Squibb. Eliquis (Apixaban) Package Insert. Bristol Myers Squibb; 2021."},{"key":"e_1_3_4_17_2","volume-title":"Andexxa Package Insert","author":"AstraZeneca Pharmaceuticals LP.","year":"2024","unstructured":"AstraZeneca Pharmaceuticals LP. Andexxa Package Insert. AstraZeneca Pharmaceuticals LP; 2024."},{"key":"e_1_3_4_18_2","volume-title":"Praxbind Package Insert","author":"Boehringer Ingelheim Pharmaceuticals, Inc","year":"2024","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Praxbind Package Insert. Boehringer Ingelheim Pharmaceuticals, Inc; 2024."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2011.01125.x"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778993"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26194"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxae109"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tru.2024.100185"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_4_25_2","unstructured":"Wells G Shea B O\u2019Connell D et al. Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed February 23 2025. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1635"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2096"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1300"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-021-00519-0"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12921"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13537"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13330"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-022-02705-6"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2024.05.005"},{"key":"e_1_3_4_35_2","unstructured":"Konkle BA. Disorders of Platelets and Vessel Wall. In: Loscalzo J Fauci A Kasper D Hauser S Longo D Jameson J. eds. Harrison\u2019s Principles of Internal Medicine 21e. McGraw-Hill Education; 2022. Accessed December 6 2024. https:\/\/accesspharmacy.mhmedical.com\/content.aspx?bookid=3095&sectionid=263545802"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.02.073"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.103.14.1838"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/1076029607303617"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12592"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12145"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18372"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231153638"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.01.014"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251322549","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251322549","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251322549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:03Z","timestamp":1777374843000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251322549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/10600280251322549"],"URL":"https:\/\/doi.org\/10.1177\/10600280251322549","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]}}}